Published in Circ Res on April 26, 2012
Inorganic phosphate accelerates the migration of vascular smooth muscle cells: evidence for the involvement of miR-223. PLoS One (2012) 1.03
Vascular remodeling in pulmonary hypertension. J Mol Med (Berl) (2013) 1.02
Holding our breath: The emerging and anticipated roles of microRNA in pulmonary hypertension. Pulm Circ (2012) 1.01
MicroRNAs in pulmonary arterial remodeling. Cell Mol Life Sci (2013) 0.99
Hypoxic pulmonary vasoconstriction in humans. Biomed Res Int (2013) 0.96
Hypoxamirs in Pulmonary Hypertension: Breathing New Life into Pulmonary Vascular Research. Cardiovasc Diagn Ther (2012) 0.84
Involvement of Rho GTPases and their regulators in the pathogenesis of hypertension. Small GTPases (2014) 0.82
Megakaryocytic leukemia 1 (MKL1) ties the epigenetic machinery to hypoxia-induced transactivation of endothelin-1. Nucleic Acids Res (2013) 0.80
Critical functions of RhoB in support of glioblastoma tumorigenesis. Neuro Oncol (2014) 0.79
RhoB controls endothelial barrier recovery by inhibiting Rac1 trafficking to the cell border. J Cell Biol (2016) 0.76
RhoB regulates the function of macrophages in the hypoxia-induced inflammatory response. Cell Mol Immunol (2015) 0.76
MicroRNA-223 Attenuates Hypoxia-induced Vascular Remodeling by Targeting RhoB/MLC2 in Pulmonary Arterial Smooth Muscle Cells. Sci Rep (2016) 0.75
CCL24 contributes to HCC malignancy via RhoB- VEGFA-VEGFR2 angiogenesis pathway and indicates poor prognosis. Oncotarget (2016) 0.75
Hypoxic Pulmonary Vasoconstriction in Humans: Tale or Myth. Open Cardiovasc Med J (2017) 0.75
Effect of fasudil on hypoxic pulmonary hypertension and right ventricular hypertrophy in rats. Int J Clin Exp Pathol (2015) 0.75
The mechanisms and significance of up-regulation of RhoB expression by hypoxia and glucocorticoid in rat lung and A549 cells. J Cell Mol Med (2016) 0.75
Fn14 is regulated via the RhoA pathway and mediates nuclear factor-kappaB activation by Angiotensin II. Am J Transl Res (2016) 0.75
Endothelium-derived microparticles from chronically thromboembolic pulmonary hypertensive patients facilitate endothelial angiogenesis. J Biomed Sci (2016) 0.75
Tipifarnib prevents development of hypoxia-induced pulmonary hypertension. Cardiovasc Res (2017) 0.75
Viral activation of stress-regulated Rho-GTPase signaling pathway disrupts sites of mRNA degradation to influence cellular gene expression. Small GTPases (2015) 0.75
Mammalian Rho GTPases: new insights into their functions from in vivo studies. Nat Rev Mol Cell Biol (2008) 8.99
Rho GTPases and actin dynamics in membrane protrusions and vesicle trafficking. Trends Cell Biol (2006) 6.33
Cytoskeletal regulation of pulmonary vascular permeability. J Appl Physiol (1985) (2001) 5.63
Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1alpha. J Clin Invest (1999) 4.00
Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem (1998) 3.97
Rho signaling, ROCK and mDia1, in transformation, metastasis and invasion. Cancer Metastasis Rev (2009) 3.13
Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies. Circulation (2010) 2.85
Dynamic changes in lung microRNA profiles during the development of pulmonary hypertension due to chronic hypoxia and monocrotaline. Arterioscler Thromb Vasc Biol (2010) 2.44
Critical role of Rho in cell transformation by oncogenic Ras. Oncogene (1995) 2.37
Regulation of TNF-alpha-induced reorganization of the actin cytoskeleton and cell-cell junctions by Rho, Rac, and Cdc42 in human endothelial cells. J Cell Physiol (1998) 2.30
RhoB is dispensable for mouse development, but it modifies susceptibility to tumor formation as well as cell adhesion and growth factor signaling in transformed cells. Mol Cell Biol (2001) 1.99
Development of farnesyl transferase inhibitors: a review. Oncologist (2005) 1.90
Hypoxia, HIF-1, and the pathophysiology of common human diseases. Adv Exp Med Biol (2000) 1.79
A role for rhoB in the delamination of neural crest cells from the dorsal neural tube. Development (1998) 1.67
MicroRNA-21 exhibits antiangiogenic function by targeting RhoB expression in endothelial cells. PLoS One (2011) 1.61
The ras-related gene rhoB is an immediate-early gene inducible by v-Fps, epidermal growth factor, and platelet-derived growth factor in rat fibroblasts. Mol Cell Biol (1991) 1.54
MicroRNA-21 plays a role in hypoxia-mediated pulmonary artery smooth muscle cell proliferation and migration. Am J Physiol Lung Cell Mol Physiol (2010) 1.52
RhoB controls Akt trafficking and stage-specific survival of endothelial cells during vascular development. Genes Dev (2003) 1.48
Rac and Rho play opposing roles in the regulation of hypoxia/reoxygenation-induced permeability changes in pulmonary artery endothelial cells. Am J Physiol Lung Cell Mol Physiol (2004) 1.48
Hypoxia and hypoxia-inducible factor-1alpha promote growth factor-induced proliferation of human vascular smooth muscle cells. Am J Physiol Heart Circ Physiol (2006) 1.48
LIM-kinase 2 and cofilin phosphorylation mediate actin cytoskeleton reorganization induced by transforming growth factor-beta. J Biol Chem (2005) 1.42
Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of RhoB. J Biol Chem (1997) 1.39
RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors. Mol Cell Biol (2000) 1.35
Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertension. Br J Pharmacol (2008) 1.35
Rac1 activity is required for the activation of hypoxia-inducible factor 1. J Biol Chem (2001) 1.28
Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation and suppress human tumor growth in nude mice. J Biol Chem (2000) 1.27
RhoA-GDP regulates RhoB protein stability. Potential involvement of RhoGDIalpha. J Biol Chem (2008) 1.25
Inhibition of RhoA/Rho kinase pathway is involved in the beneficial effect of sildenafil on pulmonary hypertension. Br J Pharmacol (2005) 1.24
Cytoskeletal effects of rho-like small guanine nucleotide-binding proteins in the vascular system. Arterioscler Thromb Vasc Biol (2001) 1.21
Long-term inhibition of Rho-kinase ameliorates hypoxia-induced pulmonary hypertension in mice. J Cardiovasc Pharmacol (2006) 1.16
Farnesyltransferase inhibitors disrupt EGF receptor traffic through modulation of the RhoB GTPase. J Cell Sci (2004) 1.16
RhoB affects macrophage adhesion, integrin expression and migration. Exp Cell Res (2007) 1.13
A negative modulatory role for rho and rho-associated kinase signaling in delamination of neural crest cells. Neural Dev (2008) 1.10
Bone morphogenetic protein 4 is induced in hepatocellular carcinoma by hypoxia and promotes tumour progression. J Pathol (2009) 1.08
Protein farnesylation in mammalian cells: effects of farnesyltransferase inhibitors on cancer cells. Cell Mol Life Sci (2001) 1.06
NPR-A-Deficient mice show increased susceptibility to hypoxia-induced pulmonary hypertension. Circulation (1999) 1.02
RhoB regulates PDGFR-beta trafficking and signaling in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol (2007) 1.02
Activation of RhoB by hypoxia controls hypoxia-inducible factor-1alpha stabilization through glycogen synthase kinase-3 in U87 glioblastoma cells. Cancer Res (2006) 0.99
ROCK I-mediated activation of NF-kappaB by RhoB. Cell Signal (2007) 0.98
Hypoxia and Rho/Rho-kinase signaling. Lung development versus hypoxic pulmonary hypertension. Adv Exp Med Biol (2003) 0.97
Hypoxic pulmonary vasoconstriction: mechanisms of oxygen-sensing. Curr Opin Anaesthesiol (2011) 0.96
Role for RhoB and PRK in the suppression of epithelial cell transformation by farnesyltransferase inhibitors. Oncogene (2003) 0.96
Regulation of Rho proteins by phosphorylation in the cardiovascular system. Trends Cardiovasc Med (2006) 0.94
Hypoxia enhances platelet-derived growth factor signaling in the pulmonary vasculature by down-regulation of protein tyrosine phosphatases. Am J Respir Crit Care Med (2010) 0.93
A role for RhoB in synaptic plasticity and the regulation of neuronal morphology. J Neurosci (2010) 0.93
Phosphorylation of RhoB by CK1 impedes actin stress fiber organization and epidermal growth factor receptor stabilization. Exp Cell Res (2008) 0.91
Interactions between calcium and reactive oxygen species in pulmonary arterial smooth muscle responses to hypoxia. Respir Physiol Neurobiol (2010) 0.91
Key role of the RhoA/Rho kinase system in pulmonary hypertension. Pulm Pharmacol Ther (2010) 0.91
Induction of small G protein RhoB by non-genotoxic stress inhibits apoptosis and activates NF-κB. J Cell Physiol (2011) 0.90
RhoB links PDGF signaling to cell migration by coordinating activation and localization of Cdc42 and Rac. J Cell Biochem (2011) 0.90
RhoA activation by hypoxia in pulmonary arterial smooth muscle cells is age and site specific. Circ Res (2004) 0.89
RhoB enhances migration and MMP1 expression of prostate cancer DU145. Exp Mol Pathol (2009) 0.82
Cell and tissue-type specific expression of Ras-related GTPase RhoB. Anticancer Res (1999) 0.82
Role of the hypoxic microenvironment in the antitumor activity of tyrosine kinase inhibitors. Curr Med Chem (2011) 0.80
Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med (2013) 5.22
Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med (2005) 4.92
Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res (2007) 3.44
MicroRNA-204 regulates Runx2 protein expression and mesenchymal progenitor cell differentiation. Stem Cells (2010) 3.16
Rising out-of-pocket spending for chronic conditions: a ten-year trend. Health Aff (Millwood) (2009) 2.98
Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies. Circulation (2010) 2.85
Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res (2007) 2.78
The Rat Genome Database (RGD): developments towards a phenome database. Nucleic Acids Res (2005) 2.77
Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J (2004) 2.75
IDO is a nodal pathogenic driver of lung cancer and metastasis development. Cancer Discov (2012) 2.56
Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid. Circulation (2012) 2.54
Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunol Rev (2008) 2.47
Mechanisms of disease: pulmonary arterial hypertension. Nat Rev Cardiol (2011) 2.39
The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov (2010) 2.23
Circulating microRNAs as novel biomarkers for platelet activation. Circ Res (2013) 2.22
Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase. Proc Natl Acad Sci U S A (2008) 2.18
Circulating endothelial progenitor cells in patients with Eisenmenger syndrome and idiopathic pulmonary arterial hypertension. Circulation (2008) 2.18
RhoB and actin polymerization coordinate Src activation with endosome-mediated delivery to the membrane. Dev Cell (2004) 2.13
Indoleamine 2,3-dioxygenase in immune suppression and cancer. Curr Cancer Drug Targets (2007) 1.86
Opposing biological functions of tryptophan catabolizing enzymes during intracellular infection. J Infect Dis (2011) 1.86
Two binding sites for [3H]PBR28 in human brain: implications for TSPO PET imaging of neuroinflammation. J Cereb Blood Flow Metab (2010) 1.85
Structure-activity study of brassinin derivatives as indoleamine 2,3-dioxygenase inhibitors. J Med Chem (2006) 1.81
Mammalian CARMIL inhibits actin filament capping by capping protein. Dev Cell (2005) 1.77
Pharmacology and therapeutic potential of interferons. Pharmacol Ther (2012) 1.76
Pivotal role for endothelial tetrahydrobiopterin in pulmonary hypertension. Circulation (2005) 1.62
Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension. Circulation (2003) 1.57
Intestinal injury and endotoxemia in children undergoing surgery for congenital heart disease. Am J Respir Crit Care Med (2011) 1.57
Dual antiplatelet therapy in cardiovascular disease: does aspirin increase clinical risk in the presence of potent P2Y12 receptor antagonists? Heart (2010) 1.57
Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med (2005) 1.56
ChIP-seq reveals cell type-specific binding patterns of BMP-specific Smads and a novel binding motif. Nucleic Acids Res (2011) 1.55
The F-box protein AhSLF-S2 physically interacts with S-RNases that may be inhibited by the ubiquitin/26S proteasome pathway of protein degradation during compatible pollination in Antirrhinum. Plant Cell (2004) 1.54
RhoB controls Akt trafficking and stage-specific survival of endothelial cells during vascular development. Genes Dev (2003) 1.48
Iron deficiency and raised hepcidin in idiopathic pulmonary arterial hypertension: clinical prevalence, outcomes, and mechanistic insights. J Am Coll Cardiol (2011) 1.48
The F-box protein AhSLF-S2 controls the pollen function of S-RNase-based self-incompatibility. Plant Cell (2004) 1.47
Recent insights into the pathogenesis and therapeutics of pulmonary hypertension. Clin Sci (Lond) (2002) 1.46
Genetic response to farnesyltransferase inhibitors: proapoptotic targets of RhoB. Cancer Biol Ther (2003) 1.46
Cyclooxygenase-3 (COX-3): filling in the gaps toward a COX continuum? Proc Natl Acad Sci U S A (2002) 1.44
Ubiquitin ligase Smurf1 mediates tumor necrosis factor-induced systemic bone loss by promoting proteasomal degradation of bone morphogenetic signaling proteins. J Biol Chem (2008) 1.41
Pluripotent factor lin-28 and its homologue lin-28b in epithelial ovarian cancer and their associations with disease outcomes and expression of let-7a and IGF-II. Eur J Cancer (2009) 1.41
Bin1 attenuation suppresses experimental colitis by enforcing intestinal barrier function. Dig Dis Sci (2012) 1.40
Emerging concepts and translational priorities in pulmonary arterial hypertension. Circulation (2008) 1.39
IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan. Oncoimmunology (2012) 1.37
Cyclin D1 functions in cell migration. Cell Cycle (2006) 1.36
The crystal structure of the BAR domain from human Bin1/amphiphysin II and its implications for molecular recognition. Biochemistry (2006) 1.35
Cyclooxygenase-1, not cyclooxygenase-2, is responsible for physiological production of prostacyclin in the cardiovascular system. Proc Natl Acad Sci U S A (2012) 1.35
The immunoregulatory enzyme IDO paradoxically drives B cell-mediated autoimmunity. J Immunol (2009) 1.34
Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. Br J Clin Pharmacol (2005) 1.29
COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs. Lancet (2008) 1.29
Targeted disruption of the murine Bin1/Amphiphysin II gene does not disable endocytosis but results in embryonic cardiomyopathy with aberrant myofibril formation. Mol Cell Biol (2003) 1.26
Alternate cyclin D1 mRNA splicing modulates p27KIP1 binding and cell migration. J Biol Chem (2008) 1.25
Ordered mesoporous silica with large cage-like pores: structural identification and pore connectivity design by controlling the synthesis temperature and time. J Am Chem Soc (2003) 1.22
Induction of IDO-1 by immunostimulatory DNA limits severity of experimental colitis. J Immunol (2010) 1.22
VEGF-C, a lymphatic growth factor, is a RANKL target gene in osteoclasts that enhances osteoclastic bone resorption through an autocrine mechanism. J Biol Chem (2008) 1.19
Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors. J Med Chem (2008) 1.18
Molecular genetic characterization of SMAD signaling molecules in pulmonary arterial hypertension. Hum Mutat (2011) 1.18
Role of TLR2, TLR4, and MyD88 in murine ozone-induced airway hyperresponsiveness and neutrophilia. J Appl Physiol (1985) (2007) 1.18
Cellular mechanisms of acetaminophen: role of cyclo-oxygenase. FASEB J (2005) 1.18
Role of nuclear receptor signaling in platelets: antithrombotic effects of PPARbeta. FASEB J (2005) 1.18
Reversion of RhoC GTPase-induced inflammatory breast cancer phenotype by treatment with a farnesyl transferase inhibitor. Mol Cancer Ther (2002) 1.18
Role of nitric oxide and prostacyclin as vasoactive hormones released by the endothelium. Exp Physiol (2007) 1.17
RGS9-2 is a negative modulator of mu-opioid receptor function. J Neurochem (2007) 1.17
Amino acid catabolism: a pivotal regulator of innate and adaptive immunity. Immunol Rev (2012) 1.16
The role of Sp1 family members, the proximal GC-rich motifs, and the upstream enhancer region in the regulation of the human cell cycle inhibitor p21WAF-1/Cip1 gene promoter. Biochemistry (2002) 1.16
Proteomic analysis of lung tissues from patients with pulmonary arterial hypertension. Circulation (2010) 1.16
A tri-continuous mesoporous material with a silica pore wall following a hexagonal minimal surface. Nat Chem (2009) 1.16
Targeting PPAR receptors in the airway for the treatment of inflammatory lung disease. Br J Pharmacol (2009) 1.13
Cigarette smoke induces IL-8, but inhibits eotaxin and RANTES release from airway smooth muscle. Respir Res (2005) 1.12
Synergistic induction of endothelin-1 by tumor necrosis factor alpha and interferon gamma is due to enhanced NF-kappaB binding and histone acetylation at specific kappaB sites. J Biol Chem (2009) 1.12
Growth differentiation factor-15 in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med (2008) 1.12
Reduced microRNA-150 is associated with poor survival in pulmonary arterial hypertension. Am J Respir Crit Care Med (2012) 1.11
Cigarette smoke activates human monocytes by an oxidant-AP-1 signaling pathway: implications for steroid resistance. Mol Pharmacol (2005) 1.11
Genotyping and expression analysis of IDO2 in human pancreatic cancer: a novel, active target. J Am Coll Surg (2009) 1.11
Antiplatelet actions of statins and fibrates are mediated by PPARs. Arterioscler Thromb Vasc Biol (2009) 1.10
Bin1 ablation increases susceptibility to cancer during aging, particularly lung cancer. Cancer Res (2007) 1.10
Protective role of peroxisome proliferator-activated receptor-β/δ in septic shock. Am J Respir Crit Care Med (2010) 1.10
Selective NOD1 agonists cause shock and organ injury/dysfunction in vivo. Am J Respir Crit Care Med (2007) 1.09
Red cell distribution width outperforms other potential circulating biomarkers in predicting survival in idiopathic pulmonary arterial hypertension. Heart (2011) 1.09
Physical and functional interactions between liver X receptor/retinoid X receptor and Sp1 modulate the transcriptional induction of the human ATP binding cassette transporter A1 gene by oxysterols and retinoids. Biochemistry (2007) 1.09
Inhibition of p53-mediated transcriptional responses by mithramycin A. Oncogene (2004) 1.08
Evidence for the involvement of type I interferon in pulmonary arterial hypertension. Circ Res (2013) 1.08
Role of prostacyclin versus peroxisome proliferator-activated receptor beta receptors in prostacyclin sensing by lung fibroblasts. Am J Respir Cell Mol Biol (2005) 1.08
Structure based development of phenylimidazole-derived inhibitors of indoleamine 2,3-dioxygenase. J Med Chem (2008) 1.07
Genetic, immunologic, and immunohistochemical analysis of the programmed death 1/programmed death ligand 1 pathway in human systemic lupus erythematosus. Arthritis Rheum (2009) 1.07
Immunotherapeutic suppression of indoleamine 2,3-dioxygenase and tumor growth with ethyl pyruvate. Cancer Res (2010) 1.06
Thrombosis is reduced by inhibition of COX-1, but unaffected by inhibition of COX-2, in an acute model of platelet activation in the mouse. PLoS One (2011) 1.06
Non-hematopoietic expression of IDO is integrally required for inflammatory tumor promotion. Cancer Immunol Immunother (2010) 1.04
Marrying immunotherapy with chemotherapy: why say IDO? Cancer Res (2005) 1.04
Differential effects of Gram-positive versus Gram-negative bacteria on NOSII and TNFalpha in macrophages: role of TLRs in synergy between the two. Br J Pharmacol (2006) 1.04
Tools and strategies for physiological genomics: the Rat Genome Database. Physiol Genomics (2005) 1.04
AhSSK1, a novel SKP1-like protein that interacts with the S-locus F-box protein SLF. Plant J (2006) 1.04